Furthermore, one of our own study has demonstrated that interferon- β (IFN-β) used to treat MS increases the KYN/TRP ratio, indirectly confirming IDO-1 enzyme mediated activation of the KP in MS (Amirkhani et al., 2005). This evidence concerns the gene IDO1 and myeloid sarcoma.